|Last updated: March 2021
Suggested citation: Jenkins, S, Bellew, B, Greenhalgh, EM & Winstanley, MH. 3.28 Health 'benefits' of smoking? In Greenhalgh, EM, Scollo, MM and Winstanley, MH [editors]. Tobacco in Australia: Facts and issues. Melbourne: Cancer Council Victoria; 2021. Available from http://www.tobaccoinaustralia.org.au/3-28-health-benefits-of-smoking-
Important note: smoking may offer a limited degree of protection in some individuals against the development of a small number of diseases, outlined below. However, this information is of little relevance to public health, given that the amount of disease that tobacco may be said to prevent is insignificant in comparison with the far greater incidence of disease caused by smoking. Tobacco products kill one in two of their long-term users. 1
Tobacco use may confer a small degree of protection against a small number of diseases and conditions, described in the sections below. However, the evidence that tobacco consumption can prevent lives being lost to these diseases and conditions is limited and further mechanistic studies are required for causal inference (see Section 3.0.1).2 Further, the number of deaths that may be prevented by smoking pales into insignificance compared to the number of deaths it has been demonstrated to cause. It is estimated that in 2015–16 tobacco use prevented 79 deaths in Australia, a very low number compared to the 20,031 deaths caused by smoking in that same year.[i]3 On the basis of these figures, tobacco might be said to save about one life for every 250 deaths it causes. Moreover, there is nothing to suggest that possible protection conferred against one disease will stop a given smoker from developing another tobacco-caused disease. So, for example, an individual who may have avoided Parkinson’s disease due to his or her smoking still runs a significant risk of dying from heart disease, lung cancer, or any of the multiplicity of other tobacco-caused diseases. Equally, smoking does not prevent Parkinson’s disease in all smokers.
While tobacco use cannot in any way be recommended as a prophylactic for these diseases and conditions, research on the mechanisms by which smoking appears to confer a protective effect against development of certain disease processes may lead to therapeutic benefits.4
3.28.1 Ulcerative colitis
Ulcerative colitis is a serious bowel disease in which the inner lining of the colon and rectum becomes inflamed and permanently damaged.5 Current smokers have a lower risk of developing ulcerative colitis, compared to non-smokers and ex-smokers,6 and according to the US Surgeon General, the evidence suggests that this protective relationship may be causal. A dose–response relationship has also been found, such that greater pack-years or numbers of cigarettes smoked per day were associated with a decreased risk of ulcerative colitis.7 Though, there is no evidence that smoking improves the disease outcomes of those with ulcerative colitis.8, 9 In addition, smokers have a greater risk of developing Crohn’s disease, another inflammatory disease of the bowel (see Section 3.12.2). Due to the devastating effects of tobacco use, smoking is not recommended as treatment for ulcerative colitis, even though one research study has canvassed this as an extreme possibility for ex-smokers with steroid-dependent and resistant ulcerative colitis.10
Nicotine in tobacco smoke is thought to be the component that is most likely to affect the development of the disease.11 Various forms of nicotine therapy are being evaluated to assess any possible benefits for individuals with this bowel disease.11 A 2004 Cochrane review found that nicotine patches could reduce flare remission of ulcerative colitis but they were not significantly better than standard medical treatment therapy and caused additional side-effects.12
It is theorised that nicotine reduces the risk of ulcerative colitis by decreasing the production of pro-inflammatory interleukins and the concentration of adrenocorticotropic hormone and cortisol, or by mediating the anti-inflammatory effect by acting on alpha-7 nicotinic acetylcholine receptors.13
3.28.2 Parkinson’s disease
An association between smoking and a lower incidence of Parkinson’s disease has been observed across cohort 14-16 and case-controlled.17 According to pooled estimates from a meta-analysis of both cohort and case-controlled studies, current and former smokers have a 41% lower risk of Parkinson’s disease relative to never smokers (RR 0.59; 95% CI, 0.56-0.62).18 The study also found an inverse dose-response relationship, such that smoking for more than 30 pack-years was associated with a 61% reduced risk relative to never smokers (RR 0.39; 95% CI, 0.29–0.53).18, 19 Based on the average data from 2014-15 and 2015-16 we can derive theoretical estimates that about 65 deaths from Parkinson’s disease are prevented by smoking in Australia annually.3, 20 Nicotine is thought to be the chemical in tobacco smoke most likely to be implicated in this finding, though the evidence is mixed and there may be other factors involved.21-23 Some research suggests that nicotine can improve compromised semantic processing in Parkinson’s disease, and also influence semantic processing in healthy older individuals;24 however, the 2014 US Surgeon General’s report found that controlled trials of the effects of nicotine on cognitive function in patients with Parkinson’s disease are limited, with inconsistent findings.7 More recent research suggests that genetics may also play a role in the association between smoking and Parkinson’s disease. Separate studies have indicated that the presence of specific variants of the RXRA and SLC17A6 genes related to xenobiotics,25 and the MAO-B26 and HLA-DRB127 genes associated with Parkinson’s disease, may be affecting the association of smoking and reduced Parkinson’s risk.
3.28.3 Endometrial cancer and uterine fibroids
Epidemiological studies have consistently reported that active cigarette smoking is inversely associated with developing cancer of the endometrium (the membrane lining of the uterus) in women who have reached menopause.28-32 A meta-analysis found that cigarette smoking was significantly associated with a reduced risk, especially so among postmenopausal women, where a 29% reduction in risk was found (RR 0.71; 95% CI, 0.65–0.78).30 Very similar results have been reported from studies conducted in Poland28, 33 although the researchers emphasise that in postmenopausal women, obesity is an important modifier of the association between cigarette smoking and the risk of endometrial cancer. The Polish researchers found that obese women showed the greatest risk reduction for current smoking (OR 0.47; 95% CI, 0.27–0.81), a finding that further underscores the need for caution in interpreting these ‘favourable effects’ of smoking, considering the toxic and carcinogenic effects of tobacco.33 Women who smoke may also have a decreased risk for uterine fibroids and endometriosis, but the evidence for this is not conclusive.32, 34 Development of endometrial cancer is predominantly influenced by exposure to the hormone oestrogen, and the protection conferred by smoking is likely to be due to the ‘anti-oestrogenic‘ effect of chemicals in tobacco smoke. This same interaction works to increase the risk among smokers of developing osteoporosis, and reaching menopause earlier than non-smokers (see Sections 3.13 and 3.6.1).32
Based on the average of data from 2014–15 and 2015–16 we can derive theoretical estimates that smoking may prevent the loss of about 16 lives from endometrial cancer in Australia annually.3 However the numbers of lives saved through the prevention of endometrial cancer among smokers are negligible compared with the number of deaths due to other diseases caused by tobacco use, including cancer of the uterine cervix.35
3.28.4 Pre-eclampsia (hypertension in pregnancy)
Pre-eclampsia is a potentially serious condition in pregnancy in which the woman develops high blood pressure, fluid retention and abnormal kidney function. Smokers are less likely to develop pre-eclampsia than non-smokers. A study using Swedish birth registry data on more than 600,000 births examined the effects of snuff use and cigarette smoking on pre-eclampsia risk and found that compared with non-tobacco users, light smokers experienced a one-third reduction in risk (OR 0.66; 95% CI, 0.61–0.71) and heavy smokers a halving of risk (OR 0.51; 95% CI, 0.44–0.58) with risk lower for term than preterm pre-eclampsia.36 A meta-analysis has also indicated that there is a significant negative association between smoking and pre-eclampsia even after adjustment for BMI, maternal age, child sex and comorbid conditions.37 The Swedish study also found that tobacco combustion products rather than nicotine are the probable protective ingredients against pre-eclampsia in cigarette smoke and further concluded that it is smoking behaviour in the middle or late rather than in the beginning of pregnancy that seems to have the greatest effect on the risk of pre-eclampsia.36 A potential mediator of these associations might be carbon monoxide (CO), as it has vasoprotective properties, and CO and CO-releasing molecules lower levels of a particular protein that is higher in women who develop preeclampsia (sFlt-1) and soluble endoglobin in in vitro cultures.7
There is also a suggestion that pre-eclampsia may occur less frequently in smokers because smoking is associated with a greater likelihood of preterm birth as well as other complications (see Section 3.7). As pre-eclampsia develops in the late stages of pregnancy, smokers are less likely to be exposed the pre-eclampsia risk period. A study has estimated that if studies controlled for the risk of pre-term birth and other biases the effect of smoking itself on pre-eclampsia risk may be non-significant.38
In 2004, the US Surgeon General concluded that ‘the decreased risk of pre-eclampsia among smokers compared with non-smokers does not outweigh the adverse outcomes that can result from prenatal smoking’ (p576).35 These conclusions are underscored by findings from a case–control study conducted in Canada where notwithstanding a (non-significant) reduction in the risk of pre-eclampsia, persistent smoking was also associated with a 10-fold increase in the risk of low birthweight (OR 10.2; 95% CI, 2.49–41.8) and a four-fold increase in the risk of preterm birth (OR 3.59; 95% CI, 1.06–12.1).39
3.28.5 Cognitive performance?
A meta-analysis of research into the effects of nicotine and smoking on human cognitive performance found positive effects of nicotine or smoking on six domains: (i) fine motor, (ii) alerting attention-accuracy, (iii) response time (RT), (iv) orienting attention-RT, (v) short-term episodic memory-accuracy, and (vi) working memory-RT (effect size range = 0.16 to 0.44).40 There is evidence that nicotine may stimulate immediate and sustained improvements in working memory,41 that nicotine replacement in smokers avoids cognitive impairment through direct pharmacological effects on brain neuronal activity,42 and that nicotine may improve prospective memory (the retrieval and implementation of a previously encoded intention).43 Note however that smoking in the longer term has been associated with cognitive decline—see Section 3.23. Nicotine receptor-based medications have been trialled for the treatment of cognitive impairments in Alzheimer’s disease, though results indicated that they did not significantly improve cognition and had added side effects.44
3.28.6 Psychiatric symptoms?
The prevalence of smoking is higher among people with psychiatric conditions.45-47 The reasons for this are complex, and vary between individuals and disorders. Smokers often perceive their smoking to be helpful in relieving or managing psychiatric symptoms,48 and many mental health workers have traditionally believed that quitting smoking will exacerbate mental illness.49 However, recent evidence suggests that the reverse is true; quitting smoking actually improves mental health, mood, and quality of life, both among the general population and among people with a psychiatric disorder.48, 50 See Section 7.12 for detailed discussion of smoking and mental health.
3.28.7 Thyroid cancer?
Some studies have suggested that smoking may be associated with a reduced risk of developing thyroid cancer,51, 52 particularly for women.32 However, one study found smoking was only associated with reduced thyroid cancer in men 53 and others have found no protective effect.54 A 2018 meta-analysis of studies concluded the association between thyroid cancer risk and smoking was inconsistent and that further research is required before a definitive statement can be made.53
3.28.8 Skin cancer?
Early evidence suggests a protective of effect of smoking for certain types of skin cancers. A meta-analysis of cohort studies found that current smoking was associated with a slightly reduced risk of developing basal cell carcinoma (RR = 0.85, 95% CI 0.75-0.96) and malignant melanoma (RR = 0.72, 95% CI 0.64-0.82). However, the study also found that smoking was associated with a moderately greater risk of developing squamous cell carcinoma (RR = 1.32, 95% CI 1.15-1.52).55 The evidence for this effect is limited, and the mechanism behind the effect and evidence for a dose-response relationship are both yet to be determined.
3.28.9 Other possible health ‘benefits’
There is some evidence that smokers56 and users of smokeless tobacco57 are less likely to develop aphthous stomatitis (common mouth ulcers). One study found that the possible protective effect of smoking was only present when there was heavy cigarette smoking or smoking for long periods of time (>5 years) and no significant associations were found between intensity or duration of smoking and clinical severity of aphthous stomatitis lesions.58 Transient increased incidence of mouth ulcers is commonly reported by individuals on quitting smoking.59
A few studies have found smokers have lower incidence of conditions affecting the immune system including celiac disease (a disorder in which eating gluten triggers an immune response in the body, causing inflammation and damage to the small intestine)60 and Sjögren's sicca (an autoimmune condition where the immune system attacks and damages secreting glands, leading to symptoms of dryness, most commonly in the eyes and mouth).61
A meta-analysis found smokers were less likely to develop acute altitude sickness compared to non-smokers (OR = 0.71, 95% CI 0.52-0.96, P = 0.03).62
[i] Resulting in a net total of 20,110 deaths attributable to smoking in 2015–16.
Relevant news and research
For recent news items and research on this topic, click here. (Last updated March 2021)
1. Doll R, Peto R, Boreham J, and Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. British Medical Journal (Clinical Research Ed.), 2004; 328(7455):1519. Available from: http://www.bmj.com/cgi/content/abstract/328/7455/1519
2. Berlin I and Tonstad S. It's time to bury the "smoker's paradox". Nicotine & Tobacco Research, 2019. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31231769
3. Whetton S, Tait RJ, Scollo M, Banks E, Chapman J, et al. Identifying the social costs of tobacco use to Australia in 2015/16. National Drug Research Institute, Curtin University, 2019. Available from: https://ndri.curtin.edu.au/NDRI/media/documents/publications/T273.pdf.
4. Baron J. Beneficial effects of nicotine and cigarette smoking: The real, the possible and the spurious. British Medical Bulletin, 1996; 52:58-73. Available from: http://bmb.oxfordjournals.org/cgi/reprint/52/1/58
5. US National Library of Medicine. Ulcerative colitis. Bethseda, Maryland: National Center for Biotechnology Information, PubMed Health, 2010. Last update: Viewed Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001296/.
6. De Saussure P, Clerson P, Prost P, Truong Tan N, Bouhnik Y, et al. Appendectomy, smoking habits and the risk of developing ulcerative colitis: A case control study in private practice setting. Gastroenterologie Clinique et Biologique, 2007.31 493–7. Available from: http://www.em-consulte.com//article/130201
7. US Department of Health and Human Services. The health consequences of smoking - 50 years of progress. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014. Available from: http://www.surgeongeneral.gov/library/reports/50-years-of-progress/.
8. To N, Ford AC, and Gracie DJ. Systematic review with meta-analysis: The effect of tobacco smoking on the natural history of ulcerative colitis. Alimentary Pharmacology & Therapeutics, 2016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27193202
9. Blackwell J, Saxena S, Alexakis C, Bottle A, Cecil E, et al. The impact of smoking and smoking cessation on disease outcomes in ulcerative colitis: A nationwide population-based study. Alimentary Pharmacology & Therapeutics, 2019; 50(5):556-67. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31389044
10. Cottone M, Georgios A, and Sinagra E Smoking therapy may be an extreme cure in exsmokers with steroid-dependent and resistant ulcerative colitis. Inflammatory Bowel Diseases, 2011.17 2213. Available from: http://onlinelibrary.wiley.com/doi/10.1002/ibd.21658/full
11. Birrenbach T and Bocker U. Inflammatory bowel disease and smoking: A review of epidemiology, pathophysiology and therapeutic implications. Inflammatory Bowel Diseases, 2004; 10(6):848-59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15626903
12. McGrath J, McDonald JWD, and MacDonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews, 2004; (4). Available from: https://doi.org//10.1002/14651858.CD004722.pub2
13. Gomes JP, Watad A, and Shoenfeld Y. Nicotine and autoimmunity: The lotus' flower in tobacco. Pharmacological Research, 2017. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29051105
14. Allam MF, Campbell M, Hofman A, Del Castillo A, and Fernández-Crehuet NR. Smoking and Parkinsons disease: Systematic review of prospective studies. Movement Disorders, 2004; 19(6):614-21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15197698
15. Li X, Li W, Liu G, Shen X, and Tang Y. Association between cigarette smoking and Parkinson's disease: A meta-analysis. Archives of Gerontology and Geriatrics, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26272284
16. Mappin-Kasirer B, Pan H, Lewington S, Kizza J, Gray R, et al. Tobacco smoking and the risk of Parkinson disease: A 65-year follow-up of 30,000 male British doctors. Neurology, 2020; 94(20):e2132-e8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32371450
17. Tanaka K, Miyake Y, Fukushima W, Sasaki S, Kiyohara C, et al. Active and passive smoking and risk of Parkinson's disease. Acta Neurologica Scandinavica, 2010; 122(6):377–82. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0404.2010.01327.x/pdf
18. Li X, Li W, Liu G, Shen X, and Tang Y. Association between cigarette smoking and Parkinson's disease: A meta-analysis. Archives of Gerontology and Geriatrics, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26272284
19. Li X, Li W, Liu G, Shen X, and Tang Y. Corrigendum to “association between cigarette smoking and parkinson’s disease: A meta-analysis” [archives of gerontology and geriatrics, 61 (2015) 510–516]. Archives of Gerontology and Geriatrics, 2016; 65:260. Available from: https://www.sciencedirect.com/science/article/pii/S0167494316300711
20. Collins D and Lapsley H. The costs of tobacco, alcohol and illicit drug abuse to Australian society in 2004/05. P3 2625. Canberra: Department of Health and Ageing, 2008. Available from: http://www.nationaldrugstrategy.gov.au/internet/drugstrategy/publishing.nsf/Content/mono64/$File/mono64.pdf.
21. Quik M, Huang L, Parameswaran N, Bordia T, Campos C, et al. Multiple roles for nicotine in Parkinson's disease. Biochemical Pharmacology 2009; 78(7):677–85. Available from: www.ncbi.nlm.nih.gov/pubmed/19433069
22. Quik M, O'Leary K, and Tanner C. Nicotine and Parkinson's disease: Implications for therapy. Movement Disorders, 2008; 23(12):1641–52. Available from: http://onlinelibrary.wiley.com/doi/10.1002/mds.21900/pdf
23. Quik M. Smoking, nicotine and Parkinson’s disease. Trends in Neurosciences, 2004; 27:561-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15331239
24. Holmes A, Copland D, Silburn P, and Chenery H. Nicotine effects on general semantic priming in Parkinson's disease. Experimental and Clinical Psychopharmacology, 2011; 19(3):215–23. Available from: www.ncbi.nlm.nih.gov/pubmed/21480732
25. Lee PC, Ahmed I, Loriot MA, Mulot C, Paul KC, et al. Smoking and Parkinson disease: Evidence for gene-by-smoking interactions. Neurology, 2018. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29352099
26. Checkoway H, Franklin GM, Costa-Mallen P, Smith-Weller T, Dilley J, et al. A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease. Neurology, 1998; 50(5):1458–61. Available from: https://n.neurology.org/content/50/5/1458
27. Chuang Y-H, Lee P-C, Vlaar T, Mulot C, Loriot M-A, et al. Pooled analysis of the HLA-DRB1 by smoking interaction in Parkinson disease. Annals of Neurology, 2017; 82(5):655–64. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798887/
28. Yang HP, Brinton LA, Platz EA, Lissowska J, Lacey JV, Jr., et al. Active and passive cigarette smoking and the risk of endometrial cancer in Poland. European Journal of Cancer, 2010; 46(4):690-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20036529
29. Polesel J, Serraino D, Zucchetto A, Lucenteforte E, Dal Maso L, et al. Cigarette smoking and endometrial cancer risk: The modifying effect of obesity. European Journal of Cancer Prevention, 2009; 18(6):476–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19609212
30. Zhou B, Yang L, Sun Q, Cong R, Gu H, et al. Cigarette smoking and the risk of endometrial cancer: A meta-analysis. The American Journal of Medicine, 2008; 121(6):501–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18501231
31. Al-Zoughool M, Dossus L, Kaaks R, Clavel-Chapelon F, Tjønneland A, et al. Risk of endometrial cancer in relationship to cigarette smoking: Results from the EPIC study. International Journal of Cancer, 2007; 121(12):2741–7. Available from: http://www3.interscience.wiley.com/journal/114297277/abstract?CRETRY=1&SRETRY=0
32. US Department of Health and Human Services. Women and smoking. A report of the Surgeon General. Atlanta, Georgia: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. Atlanta, Georgia, 2001. Available from: http://www.cdc.gov/tobacco/data_statistics/sgr/sgr_2001/index.htm.
33. Polesel J, Serraino D, Zucchetto A, Lucenteforte E, Dal Maso L, et al. Cigarette smoking and endometrial cancer risk: The modifying effect of obesity. European Journal of Cancer Prevention, 2009; [Epub ahead of print]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19609212
34. Chiaffarino F, Ricci E, Cipriani S, Chiantera V, and Parazzini F. Cigarette smoking and risk of uterine myoma: Systematic review and meta-analysis. The European Journal of Obstetrics & Gynecology and Reproductive Biology, 2016; 197:63–71. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0301211515004145?via%3Dihub
35. US Department of Health and Human Services. The health consequences of smoking: A report of the Surgeon General. Atlanta, Georgia: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. Available from: http://www.cdc.gov/tobacco/data_statistics/sgr/index.htm.
36. Wikstrom A, Stephansson O, and Cnattingius S. Tobacco use during pregnancy and preeclampsia risk. Effects of cigarette smoking and snuff. Hypertension, 2010; 55(5):1254–9. Available from: http://hyper.ahajournals.org/cgi/content/full/55/5/1254
37. Wei J, Liu CX, Gong TT, Wu QJ, and Wu L. Cigarette smoking during pregnancy and preeclampsia risk: A systematic review and meta-analysis of prospective studies. Oncotarget, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26498356
38. Luque-Fernandez MA, Zoega H, Valdimarsdottir U, and Williams MA. Deconstructing the smoking-preeclampsia paradox through a counterfactual framework. European Journal of Epidemiology, 2016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26975379
39. Xiong X, Zhang J, and Fraser W. Quitting smoking during early versus late pregnancy: The risk of preeclampsia and adverse birth outcomes. Journal of Obstetrics and Gynaecology Canada, 2009; 31(8):702–7. Available from: http://www.sogc.org/jogc/abstracts/full/200908_Obstetrics_1.pdf
40. Heishman S, Kleykamp B, and Singleton E. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology, 2010; 210(4):453–69. Available from: www.ncbi.nlm.nih.gov/pubmed/20414766
41. Castner S, Smagin G, Piser T, Wang Y, Smith J, et al. Immediate and sustained improvements in working memory after selective stimulation of alpha7 nicotinic acetylcholine receptors. Biological Psychiatry, 2011; 69(1):12–8. Available from: http://www.biologicalpsychiatryjournal.com/article/PIIS0006322310008231/fulltext
42. Beaver JD, Long CJ, Cole DM, Durcan MJ, Bannon LC, et al. The effects of nicotine replacement on cognitive brain activity during smoking withdrawal studied with simultaneous fmri/eeg. Neuropsychopharmacology, 2011; 26(9):1792–800. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21544072
43. Rusted J, Sawyer R, Jones C, Trawley S, and Marchant N. Positive effects of nicotine on cognition: The deployment of attention for prospective memory. Psychopharmacology, 2009; 202((1–3)):93–102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18815772
44. Hoskin JL, Al-Hasan Y, and Sabbagh MN. Nicotinic acetylcholine receptor agonists for the treatment of Alzheimer's dementia: An update. Nicotine & Tobacco Researchs, 2018. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30137524
45. Lasser K, Boyd L, Woolhandler S, Himmelstein S, McCormick D, et al. Smoking and mental illness: A population-based prevalence study. Journal of the American Medical Association, 2000; 284(2):2606–10. Available from: http://jama.ama-assn.org/cgi/content/full/284/20/2606
46. McNeill A. Smoking and mental health: A review of the literature. London: Smokefree London Programme, 2001. Available from: http://www.ash.org.uk/html/policy/menlitrev.pdf.
47. Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, et al. People living with psychotic illness: An Australian study 1997-98. Canberra: Mental Health Branch, Commonwealth Department of Health and Aged Care, 1999.
48. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, et al. Change in mental health after smoking cessation: Systematic review and meta-analysis. British Medical Journal, 2014; 348:g1151. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24524926
49. Mendelsohn CP, Kirby DP, and Castle DJ. Smoking and mental illness. An update for psychiatrists. Australasian Psychiatry, 2015; 23(1):37–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25512967
50. Taylor GMJ, Lindson N, Farley A, Leinberger-Jabari A, Sawyer K, et al. Smoking cessation for improving mental health. Cochrane Database of Systematic Reviews, 2021; (3). Available from: https://doi.org//10.1002/14651858.CD013522.pub2
51. Czarnywojtek A, Kurdybacha P, Florek E, Warmuz-Stangierska I, Zdanowska J, et al. [smoking and thyroid diseases-what is new?]. Przeglad Lekarski, 2010; 67(10):1056-60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21355496
52. Kreiger N and Parkes R. Cigarette smoking and the risk of thyroid cancer. European Journal of Cancer, 2000; 36(15):1969-73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11000579
53. Cho YA and Kim J. Thyroid cancer risk and smoking status: A meta-analysis. Cancer Causes and Control, 2014; 25(9):1187-95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24981099
54. Bandurska-Stankiewicz E, Aksamit-Bialoszewska E, Rutkowska J, Stankiewicz A, and Shafie D. The effect of nutritional habits and addictions on the incidence of thyroid carcinoma in the olsztyn province of Poland. Endokrynologia Polska, 2011; 62(2):145-50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21528477
55. Arafa A, Mostafa A, Navarini AA, and Dong JY. The association between smoking and risk of skin cancer: A meta-analysis of cohort studies. Cancer Causes Control, 2020. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32458137
56. Rivera-Hidalgo F, Shulman J, and Beach M. The association of tobacco and other factors with recurrent aphthous stomatitis in a US adult population. Oral Diseases, 2004; 10(6):335-45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15533208
57. Grady D, Ernster V, Stillman L, and Greenspan J. Smokeless tobacco use prevents aphthous stomatitis. Oral Surgery, Oral Medicine, and Oral Pathology, 1992; 74:463-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1408021
58. Sawair FA. Does smoking really protect from recurrent aphthous stomatitis? Therapeutic Clinical Risk Management, 2010; 6:573-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21151626
59. Ussher M, West R, Steptoe A, and McEwen A. Increase in common cold symptoms and mouth ulcers following smoking cessation. Tobacco Control, 2003; 12:86-8. Available from: http://tc.bmjjournals.com/cgi/content/abstract/12/1/86
60. Wijarnpreecha K, Lou S, Panjawatanan P, Cheungpasitporn W, Pungpapong S, et al. Cigarette smoking and risk of celiac disease: A systematic review and meta-analysis. United European Gastroenterology Journal, 2018; 6(9):1285–93. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206527/pdf/10.1177_2050640618786790.pdf
61. Stone DU, Fife D, Brown M, Earley KE, Radfar L, et al. Effect of tobacco smoking on the clinical, histopathological, and serological manifestations of Sjogren's syndrome. PLoS One, 2017; 12(2):e0170249. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28166540
62. Xu C, Lu HX, Wang YX, Chen Y, Yang SH, et al. Association between smoking and the risk of acute mountain sickness: A meta-analysis of observational studies. Military Medical Research, 2016; 3:37. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27980800